Clinical Trial Update: The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma [Phase 1]

View source ↗

Summary

This document summarizes a Phase 1 trial evaluating anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell lymphoma. The snippet provides s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Anti-CD20 CAR-T cells (CD20-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Xin Wang | Conditions: Relapsed or Refractory B-cell Lymphomas | Phase 1 | Status: UNKNOWN